Relay Therapeutics Reports Third Quarter 2026 Financial Results and Corporate Updates
Globe Newswire•04/11/2026•16:05 ET
0
Key Highlights
- ➤ReDiscover-2 enrollment expected to complete in mid-2027, about one year faster than recent benchmarks
- ➤Cash, cash equivalents and investments totaled $848.6 million at September 30, 2026
- ➤Cash runway expected to fund operating expenses and capital expenditures into 2029
- ➤Relay announced its first known mutant-selective TIE2 inhibitor, now in late-stage preclinical development
- ➤Q3 net loss widened to $81.7 million, or $0.37 per share, from $74.1 million
Expert Statements
Sanjiv Patel, President and Chief Executive Officer of Relay Therapeutics
“This quarter, we are very pleased by the pace of enrollment of our ReDiscover-2 trial for second-line breast cancer and also look forward to sharing updated ReInspire data for vascular anomalies at ASH. In addition, we continue to prepare for our frontline breast cancer trial testing the selective-selective combination of zovegalisib and atirmociclib, and we were highly encouraged by the data we saw from Pfizer’s FourLight-1 trial, which we believe showed the potential advantage of a CDK4-selective approach”
Sanjiv Patel, President and Chief Executive Officer of Relay Therapeutics
“As we move toward potential launches, we are excited to bring Shannon Campbell onto the Relay team, where she will bring decades of experience in helping companies like ours prepare for commercialization. All of this drives us toward our mission of bringing potentially life-changing therapies to patients across multiple PI3Kα opportunities.”
Phase 3 ReDiscover-2 trial in 2L breast cancer expected to complete enrollment in mid-2027
Updated data from ongoing Phase 1/2 ReInspire trial of zovegalisib in vascular anomalies to be featured in oral presentation at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition; Relay to hold conference call to discuss data and provide regulatory update
Get started
Create a free account to read the full story.